MLTX Stock Price, MoonLake Immunotherapeutics Quote, Chart

Market Summary

USD42.43-0.82

Market Closed

-1.90%

MLTX Stock Price

View Fullscreen

MLTX RSI Chart

MLTX Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-53.83

Price/Free Cashflow

-48.4

MLTX Price/Earnings (Trailing)

MLTX Profitability

Return on Equity

-7.81%

Return on Assets

-7.35%

Free Cashflow Yield

-2.07%

MLTX Fundamentals

MLTX Earnings

Earnings (TTM)

-38.7M

Earnings Growth (Yr)

60.1%

Earnings Growth (Qtr)

49.89%

Breaking Down MLTX Revenue

Last 7 days

-2.5%

Last 30 days

-18.0%

Last 90 days

-25.2%

How does MLTX drawdown profile look like?

MLTX Financial Health

Current Ratio

51.59

MLTX Investor Care

Shares Dilution (1Y)

67.30%

Diluted EPS (TTM)

-0.74

Tracking the Latest Insider Buys and Sells of MoonLake Immunotherapeutics

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	santos da silva jorge	sold	-264,919	55.89	-4,740	chief executive officer
Feb 28, 2024	reich kristian	sold	-1,544,950	55.00	-28,090	chief scientific officer
Feb 28, 2024	reich kristian	sold	-1,755,050	55.00	-31,910	chief scientific officer
Feb 28, 2024	santos da silva jorge	sold	-3,083,580	55.00	-56,065	chief executive officer
Feb 27, 2024	reich kristian	sold	-1,618,700	55.00	-29,431	chief scientific officer
Feb 27, 2024	reich kristian	sold	-1,622,000	55.00	-29,491	chief scientific officer
Feb 27, 2024	santos da silva jorge	sold	-3,454,550	55.00	-62,810	chief executive officer
Feb 21, 2024	santos da silva jorge	sold	-62,178	55.27	-1,125	chief executive officer
Feb 21, 2024	reich kristian	sold	-31,465	55.3	-569	chief scientific officer
Feb 21, 2024	reich kristian	sold	-28,152	55.31	-509	chief scientific officer

Which funds bought or sold MLTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	Cutler Group LLC / CA	added	127	59,000	125,000	0.04%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-5,797	-	-%
Apr 16, 2024	Stratos Wealth Partners, LTD.	sold off	-100	-202,307	-	-%
Apr 12, 2024	DNB Asset Management AS	new	-	285,206	285,206	-%
Apr 10, 2024	Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	new	-	13,828,800	13,828,800	3.15%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	50.66	138,657	371,217	-%
Mar 11, 2024	VANGUARD GROUP INC	added	441	3,673,460	4,448,150	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	212	12,742,800	18,254,000	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	new	-	4,976,020	4,976,020	0.11%
Feb 20, 2024	Quarry LP	new	-	51,332	51,332	0.01%

Are Funds Buying or Selling MLTX?

Are funds buying MLTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MLTX

No. of Funds

Unveiling MoonLake Immunotherapeutics's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 05, 2024	biotechnology value fund l p	17.9%	11,265,678	SC 13D/A
Feb 15, 2024	merck healthcare kgaa	4.7%	2,787,509	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.3%	6	SC 13G/A
Feb 14, 2024	chen bihua	14.17%	8,494,151	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G

Recent SEC filings of MoonLake Immunotherapeutics

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 11, 2024	8-K	Current Report
Mar 05, 2024	SC 13D/A	13D - Major Acquisition
Feb 29, 2024	10-K	Annual Report
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report

Peers (Alternatives to MoonLake Immunotherapeutics)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

MoonLake Immunotherapeutics News

Latest updates

MoonLake Immunotherapeutics Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Assets	5.3%	527	500	507	67.00	77.00	89.00	98.00	12.00	10.00	116	116	116	117	-
Current Assets	2.8%	514	500	506	67.00	77.00	89.00	98.00	12.00	10.00	1.00	1.00	1.00	2.00	-
Cash Equivalents	41.8%	451	318	502	50.00	40.00	41.00	93.00	9.00	8.00	1.00	2.00	1.00	-	-
Net PPE	711.9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-
Liabilities	23.4%	13.00	11.00	8.00	8.00	8.00	6.00	4.00	37.00	21.00	6.00	4.00	4.00	4.00	-
Current Liabilities	-3.3%	10.00	10.00	7.00	7.00	8.00	6.00	4.00	37.00	21.00	2.00	0.00	0.00	0.00	0.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	15.00	-	-	-	-	-
Shareholder's Equity	16.6%	496	425	499	59.00	49.00	83.00	95.00	24.00	-	-	1.00	5.00	5.00	0.00
Retained Earnings	-6.8%	-116	-109	-99.79	-89.66	-80.65	-68.79	-58.68	-69.52	-53.64	-4.84	-0.32	-0.17	-2.52	0.00
Additional Paid-In Capital	14.8%	610	531	590	131	129	124	122	44.00	42.00	-	5.00	5.00	5.00	0.00
Shares Outstanding	8.0%	49.00	45.00	44.00	39.00	29.00	26.00	20.00	53.00	8.00	2.00	16.00	-	6.00	3.00
Minority Interest	-72.5%	18.00	65.00	9.00	17.00	20.00	27.00	31.00	-	-	-	-	-	-	-
Float	-	-	-	1,120	-	-	-	34.00	-	-	-	119	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-33.4%	-12,344	-9,250	-12,158	-9,024	-11,595	-9,351	-20,760	-14,185	27,112	-2,018	-25,596	-107	-
Share Based Compensation	12.6%	1,606	1,426	1,498	2,577	2,597	2,585	2,484	1,989	-	-	-	-	-
Cashflow From Investing	167.0%	116,867	-174,375	12,676	19,649	9,901	-42,226	2*	-16.01	-	-11.65	-	-	-
Cashflow From Financing	-	28,416	-	451,285	-	4.00	-	104,685	15,004	-28,322	498	27,824	-58.06	-

MLTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ (31,801,880)	$ (42,048,954)
General and administrative	(22,321,216)	(23,012,463)
Total operating expenses	(54,123,096)	(65,061,417)
Operating loss	(54,123,096)	(65,061,417)
Other income, net	10,138,367	591,732
Loss before income tax	(43,984,729)	(64,469,685)
Income tax expense	(94,388)	(36,366)
Net loss	(44,079,117)	(64,506,051)
Of which: net loss attributable to controlling interests shareholders	(36,007,260)	(49,973,249)
Of which: net loss attributable to noncontrolling interests shareholders	(8,071,857)	(14,532,802)
Net unrealized gain on marketable securities and short-term investments	2,330,101	390,753
Actuarial income (loss) on employee benefit plans	(336,579)	269,893
Other comprehensive income	1,993,522	660,646
Comprehensive loss	(42,085,595)	(63,845,405)
Comprehensive loss attributable to controlling interests shareholders	(34,511,723)	(49,437,461)
Comprehensive loss attributable to noncontrolling interests	$ (7,573,872)	$ (14,407,944)
Weighted-average number of shares, basic (in shares)	49,122,534	29,361,353
Weighted-average number of shares, diluted (in shares)	49,122,534	29,361,353
Basic net loss per share attributable to controlling interest shareholders (USD per share)	$ (0.73)	$ (1.70)
Diluted net loss per share attributable to controlling interest shareholders (USD per share)	$ (0.73)	$ (1.70)
Common Class A
Operating expenses
Weighted-average number of shares, basic (in shares)	49,122,534	29,361,353
Weighted-average number of shares, diluted (in shares)	49,122,534	29,361,353
Basic net loss per share attributable to controlling interest shareholders (USD per share)	$ (0.73)	$ (1.70)
Diluted net loss per share attributable to controlling interest shareholders (USD per share)	$ (0.73)	$ (1.70)

MLTX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 451,169,337	$ 39,505,627
Short-term marketable debt securities	59,838,900	32,609,108
Other receivables	1,056,862	217,129
Prepaid expenses - current	2,102,203	4,179,468
Total current assets	514,167,302	76,511,332
Non-current assets
Operating lease right-of-use assets	3,628,480	282,580
Property and equipment, net	320,865	49,389
Prepaid expenses - non-current	8,423,468	0
Total non-current assets	12,372,813	331,969
Total assets	526,540,115	76,843,301
Current liabilities
Trade and other payables	1,837,684	254,972
Short-term portion of operating lease liabilities	1,197,876	153,629
Accrued expenses and other current liabilities	6,930,120	7,256,845
Total current liabilities	9,965,680	7,665,446
Non-current liabilities
Long-term portion operating lease liability	2,499,990	128,951
Pension liability	583,426	282,206
Total non-current liabilities	3,083,416	411,157
Total liabilities	13,049,096	8,076,603
Commitments and contingencies
Equity (deficit)
Additional paid-in capital	609,969,236	129,192,291
Accumulated deficit	(116,657,472)	(80,650,212)
Accumulated other comprehensive income	2,357,621	350,946
Total shareholders’ equity	495,675,683	48,898,296
Noncontrolling interests	17,815,336	19,868,402
Total equity	513,491,019	68,766,698
Total liabilities and equity	526,540,115	76,843,301
Common Class A
Equity (deficit)
Common Shares	6,047	3,898
Common Class C
Equity (deficit)
Common Shares	$ 251	$ 1,373

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

CEO	Dr. Jorge Santos da Silva
WEBSITE	moonlaketx.com
INDUSTRY	Biotechnology
EMPLOYEES	20

MoonLake Immunotherapeutics Frequently Asked Questions

What is the ticker symbol for MoonLake Immunotherapeutics? What does MLTX stand for in stocks?

MLTX is the stock ticker symbol of MoonLake Immunotherapeutics. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MoonLake Immunotherapeutics (MLTX)?

As of Wed Apr 24 2024, market cap of MoonLake Immunotherapeutics is 2.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MLTX stock?

You can check MLTX's fair value in chart for subscribers.

What is the fair value of MLTX stock?

You can check MLTX's fair value in chart for subscribers. The fair value of MoonLake Immunotherapeutics is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MoonLake Immunotherapeutics is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MLTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MoonLake Immunotherapeutics a good stock to buy?

The fair value guage provides a quick view whether MLTX is over valued or under valued. Whether MoonLake Immunotherapeutics is cheap or expensive depends on the assumptions which impact MoonLake Immunotherapeutics's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MLTX.